転移性がん治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、がんタイプ別、エンドユーザー別、地域別、競合別、2020-2030年

転移性がん治療薬の世界市場規模は2024年に787億5,000万米ドルとなり、2030年までのCAGRは7.35%で、予測期間中に目覚ましい成長が予測されています。

転移性がん治療薬の世界市場は、製薬業界の中でも重要かつ急速に発展している分野であり、元の部位を超えて転移したがんに対する先進的な治療法の開発に専念しています。これらの薬剤は、腫瘍の進行を遅らせ、症状を管理し、患者のQOLを高めるように設計されています。

大幅な進歩にもかかわらず、治療費の高騰や特定のがん種における進歩の限界など、市場は引き続き重要な課題に直面しています。例えば、膵臓がんは依然として致死率が高く、フォルフィリノックスなどの標準治療の効果は限定的です。

しかし、がん罹患率の上昇、治療法における継続的な技術革新、戦略的な業界提携などが原動力となり、力強い成長の見込みは残されています。持続的な市場拡大のためには、特に治療が困難ながんにおいて、治療費の妥当性と有効性に関する問題に対処することが不可欠です。

主要市場促進要因

転移性がんの有病率の上昇

主な市場課題

薬剤開発コストと時間的制約

主要市場動向

免疫療法の優位性

研究者らは、奏効率を高め、耐性を克服するために、免疫療法と標的療法や化学療法などの他の治療法との組み合わせを模索しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 転移性がん治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別（化学療法、免疫療法、ホルモン療法、標的療法、その他）
  • がんの種類別（乳がん、肺がん、前立腺がん、黒色腫、大腸がん、その他）
  • エンドユーザー別（病院・診療所、外来センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の転移性がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の転移性がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の転移性がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の転移性がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの転移性がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の転移性がん治療薬市場：SWOT分析

第14章 競合情勢

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca Plc
• Novartis AG
• Eli Lilly & Co.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Amgen Inc.
• Sanofi SA.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Metastatic Cancer Drugs Market was valued at USD 78.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.35% through 2030. The Global Metastatic Cancer Drugs Market is a vital and rapidly evolving sector within the pharmaceutical industry, dedicated to developing advanced therapies for cancers that have spread beyond their original site. These drugs are designed to slow tumor progression, manage symptoms, and enhance patients' quality of life.

Despite significant advancements, the market continues to face key challenges, including high treatment costs and limited progress in certain cancer types. For instance, pancreatic cancer remains highly lethal, with standard treatments such as Folfirinox offering only limited efficacy.

However, strong growth prospects remain, driven by rising cancer prevalence, continuous innovations in therapy, and strategic industry collaborations. To ensure sustained market expansion, addressing issues related to treatment affordability and effectiveness, particularly for hard-to-treat cancers, will be essential.

Key Market Drivers

The Rising Prevalence Of Metastatic Cancer

The rising prevalence of metastatic cancer is a significant market driver in the Global Metastatic Cancer Drugs Market. This phenomenon is multifaceted and can be attributed to several interconnected reasons, all of which have a substantial impact on the demand for metastatic cancer drugs.

One of the primary factors contributing to the increasing prevalence of metastatic cancer is the global demographic shift toward an aging population. As people age, their risk of developing cancer, including metastatic cancer, increases. This is because the incidence of cancer tends to rise with age, and as a result, there is a growing pool of potential patients requiring cancer treatment. Modern lifestyle choices have also played a pivotal role in the rising incidence of metastatic cancer. Factors such as poor diet, lack of physical activity, smoking, and excessive alcohol consumption are known risk factors for various types of cancer, including those that can metastasize. As these unhealthy habits become more prevalent in society, the occurrence of cancer cases, including metastatic ones, continues to rise. Environmental factors, including exposure to carcinogens and pollutants, have been linked to an increased risk of cancer. Industrialization, urbanization, and the expansion of certain industries have led to greater exposure to harmful substances, contributing to the incidence of metastatic cancer in some regions.

Key Market Challenges

Drug Development Costs and Time Constraints

Developing metastatic cancer drugs is a resource-intensive and time-consuming process. Clinical trials alone can take several years and cost billions of dollars. The need for extensive research, preclinical studies, regulatory approvals, and post-marketing surveillance significantly adds to the expenses and timelines. Additionally, the high attrition rate of experimental drugs during clinical trials further compounds the costs and extends development timelines.

Key Market Trends

Immunotherapy Dominance

Immunotherapy has emerged as a dominant trend in the treatment of metastatic cancer due to its remarkable efficacy and potential for long-lasting responses. Key factors contributing to this trend include:

Immunotherapies, such as immune checkpoint inhibitors (e.g., PD-1 and PD-L1 inhibitors) and CAR-T cell therapies, have demonstrated unprecedented success in treating certain metastatic cancers. Patients who had limited treatment options in the past are now experiencing durable responses and improved survival rates. Immunotherapy can be personalized based on a patient's immune profile and tumor characteristics. This tailoring of treatment enhances its effectiveness and minimizes adverse effects, making it an attractive option.

Researchers are exploring combinations of immunotherapies with other treatment modalities, such as targeted therapies and chemotherapy, to enhance response rates and overcome resistance.

Key Market Players

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca Plc
• Novartis AG
• Eli Lilly & Co.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Amgen Inc.
• Sanofi SA

Report Scope:

In this report, the Global Metastatic Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metastatic Cancer Drugs Market, By Therapy Type:

• Chemotherapy
• Immunotherapy
• Hormone Therapy
• Targeted Therapy
• Others

Metastatic Cancer Drugs Market, By Type of Cancer:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Melanoma
• Colorectal Cancer
• Others

Metastatic Cancer Drugs Market, By End User:

• Hospital & Clinics
• Ambulatory Centers
• Others

Metastatic Cancer Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Cancer Drugs Market.

Available Customizations:

Global Metastatic Cancer Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Metastatic Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Others)
  • 5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Colorectal Cancer, Others)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Centers, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Metastatic Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Type of Cancer
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metastatic Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Type of Cancer
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Metastatic Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Type of Cancer
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Metastatic Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Type of Cancer
      • 6.3.3.2.3. By End User

7. Europe Metastatic Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Type of Cancer
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metastatic Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Type of Cancer
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Metastatic Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Type of Cancer
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Metastatic Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Type of Cancer
      • 7.3.3.2.3. By End User
  • 7.3.4. France Metastatic Cancer Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Type of Cancer
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Metastatic Cancer Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Type of Cancer
      • 7.3.5.2.3. By End User

8. Asia-Pacific Metastatic Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Type of Cancer
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Metastatic Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Type of Cancer
      • 8.3.1.2.3. By End User
  • 8.3.2. India Metastatic Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Type of Cancer
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Metastatic Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Type of Cancer
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Metastatic Cancer Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Type of Cancer
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Metastatic Cancer Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Type of Cancer
      • 8.3.5.2.3. By End User

9. South America Metastatic Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Type of Cancer
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metastatic Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Type of Cancer
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Metastatic Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Type of Cancer
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Metastatic Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Type of Cancer
      • 9.3.3.2.3. By End User

10. Middle East and Africa Metastatic Cancer Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Type of Cancer
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metastatic Cancer Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Type of Cancer
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Metastatic Cancer Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Type of Cancer
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Metastatic Cancer Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Type of Cancer
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Metastatic Cancer Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bristol-Myers Squibb Company
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Merck & Co., Inc.
• 14.3. AstraZeneca Plc
• 14.4. Novartis AG
• 14.5. Eli Lilly & Co.
• 14.6. Pfizer Inc.
• 14.7. F. Hoffmann-La Roche Ltd.
• 14.8. Johnson & Johnson
• 14.9. Amgen Inc.
• 14.10.Sanofi SA.

15. Strategic Recommendations

16. About Us & Disclaimer